MCF-10AT: A Model for Human Breast Cancer Development

Overview

Journal Breast J

Publisher Wiley

Date 2001 May 12

PMID 11348271

Citations 24

Authors

Gloria H Heppner

Sandra R Wolman

Affiliations

Soon will be listed here.

Abstract

A number of lesions, collectively termed Proliferative Breast Disease (PBD), have been associated with high risk of developing breast cancer. Understanding of the natural history of PBD and its relationship to breast cancer progression has been hampered by the lack of an experimental model. MCF-10AT cells are of human, breast epithelial cell origin. They grow as xenografts in immune-incompetent mice where they produce normal-appearing ducts, atypical hyperplasia, carcinoma-in-situ, and invasive carcinoma. Estrogen supplementation of the mice accelerates development of cancer. The MCF-10AT model of PBD offers a new approach to the study of early breast cancer progression and its prevention.

Citing Articles

Eugenol inhibits NEAT1 as a ceRNA in pre-cancerous breast lesions.

Liu Y, Zhang G, Ma Y, Ma M, Jiang X Heliyon. 2025; 11(1):e41353.

PMID: 39811361 PMC: 11732537. DOI: 10.1016/j.heliyon.2024.e41353.

Identification of epigenetic modulators as determinants of nuclear size and shape.

Schibler A, Jevtic P, Pegoraro G, Levy D, Misteli T Elife. 2023; 12.

PMID: 37219077 PMC: 10259489. DOI: 10.7554/eLife.80653.

Novel cryo-tomography workflow reveals nanometer-scale responses of epithelial cells to matrix stiffness and dimensionality.

Gaietta G, Kai F, Swift M, Weaver V, Volkmann N, Hanein D Mol Biol Cell. 2022; 33(14):br28.

PMID: 36287913 PMC: 9727794. DOI: 10.1091/mbc.E22-03-0092.

Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma.

Brock E, Jackson R, Boerner J, Li Q, Tennis M, Sloane B PLoS One. 2021; 16(5):e0252314.

PMID: 34048471 PMC: 8162601. DOI: 10.1371/journal.pone.0252314.

Cell Adhesiveness Serves as a Biophysical Marker for Metastatic Potential.

Beri P, Popravko A, Yeoman B, Kumar A, Chen K, Hodzic E Cancer Res. 2019; 80(4):901-911.

PMID: 31857292 PMC: 7024658. DOI: 10.1158/0008-5472.CAN-19-1794.